Stock KRON KRONOS BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Kronos Bio, Inc.

Equities

KRON

US50107A1043

Market Closed - Nasdaq
Other stock markets
 01:30:00 14/06/2024 am IST 		5-day change 1st Jan Change
1.06 USD -17.19% Intraday chart for Kronos Bio, Inc. +45.80% -15.20%
23/05 Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology Annual Meeting CI
21/05 Kronos Bio, Inc. Announces Executive Changes CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Kronos Bio, Inc. to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology Annual Meeting
CI
Kronos Bio to Participate in Three Upcoming Healthcare Conferences and Events
GL
Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer 
GL
Kronos Bio, Inc. Announces Executive Changes
CI
Kronos Bio, Inc. Announces Chief Financial Officer Changes
CI
Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M
MT
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kronos Bio Reports First-Quarter 2024 Financial Results
GL
Kronos Bio Reports First-Quarter 2024 Financial Results
AQ
Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
GL
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M
MT
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial Results
GL
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash Runway
GL
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study
CI
Kronos Bio Plans to Reduction in Force
CI
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
GL
Kronos Bio Announces Participation in 44th Annual Cowen Health Care Conference
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KRON Stock
  4. News Kronos Bio, Inc.